These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39236712)

  • 1. Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma.
    Zhong Y; Geng F; Mazik L; Yin X; Becker AP; Mohammed S; Su H; Xing E; Kou Y; Chiang CY; Fan Y; Guo Y; Wang Q; Li PK; Mo X; Lefai E; He L; Cheng X; Zhang X; Chakravarti A; Guo D
    Cell Rep Med; 2024 Sep; 5(9):101706. PubMed ID: 39236712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis.
    Geng F; Cheng X; Wu X; Yoo JY; Cheng C; Guo JY; Mo X; Ru P; Hurwitz B; Kim SH; Otero J; Puduvalli V; Lefai E; Ma J; Nakano I; Horbinski C; Kaur B; Chakravarti A; Guo D
    Clin Cancer Res; 2016 Nov; 22(21):5337-5348. PubMed ID: 27281560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy activation, lipotoxicity and lysosomal membrane permeabilization synergize to promote pimozide- and loperamide-induced glioma cell death.
    Meyer N; Henkel L; Linder B; Zielke S; Tascher G; Trautmann S; Geisslinger G; Münch C; Fulda S; Tegeder I; Kögel D
    Autophagy; 2021 Nov; 17(11):3424-3443. PubMed ID: 33461384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
    Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
    J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
    Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
    Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
    Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
    Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
    Wang L; Liu Y; Zhao TL; Li ZZ; He JY; Zhang BJ; Du HZ; Jiang JW; Yuan ST; Sun L
    Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
    Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
    Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.
    Cardoso HJ; Figueira MI; Vaz CV; Carvalho TMA; Brás LA; Madureira PA; Oliveira PJ; Sardão VA; Socorro S
    Cell Oncol (Dordr); 2021 Apr; 44(2):385-403. PubMed ID: 33464483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-153 regulates glutamine metabolism in glioblastoma through targeting glutaminase.
    Liu Z; Wang J; Li Y; Fan J; Chen L; Xu R
    Tumour Biol; 2017 Feb; 39(2):1010428317691429. PubMed ID: 28218035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
    Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
    J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
    Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
    J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway.
    Restall IJ; Cseh O; Richards LM; Pugh TJ; Luchman HA; Weiss S
    Cancer Res; 2020 Dec; 80(24):5478-5490. PubMed ID: 33106333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamine Metabolism Heterogeneity in Glioblastoma Unveils an Innovative Combination Therapy Strategy.
    Fu H; Wu S; Shen H; Luo K; Huang Z; Lu N; Li Y; Lan Q; Xian Y
    J Mol Neurosci; 2024 May; 74(2):52. PubMed ID: 38724832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
    Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
    Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.
    Schulte ML; Fu A; Zhao P; Li J; Geng L; Smith ST; Kondo J; Coffey RJ; Johnson MO; Rathmell JC; Sharick JT; Skala MC; Smith JA; Berlin J; Washington MK; Nickels ML; Manning HC
    Nat Med; 2018 Feb; 24(2):194-202. PubMed ID: 29334372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity.
    Oizel K; Chauvin C; Oliver L; Gratas C; Geraldo F; Jarry U; Scotet E; Rabe M; Alves-Guerra MC; Teusan R; Gautier F; Loussouarn D; Compan V; Martinou JC; Vallette FM; Pecqueur C
    Clin Cancer Res; 2017 Oct; 23(20):6292-6304. PubMed ID: 28720668
    [No Abstract]   [Full Text] [Related]  

  • 18. Control of glutamine metabolism by the tumor suppressor Rb.
    Reynolds MR; Lane AN; Robertson B; Kemp S; Liu Y; Hill BG; Dean DC; Clem BF
    Oncogene; 2014 Jan; 33(5):556-66. PubMed ID: 23353822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
    van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
    Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neddylation inhibition induces glutamine uptake and metabolism by targeting CRL3
    Zhou Q; Lin W; Wang C; Sun F; Ju S; Chen Q; Wang Y; Chen Y; Li H; Wang L; Hu Z; Jin H; Wang X; Sun Y
    Nat Commun; 2022 May; 13(1):3034. PubMed ID: 35641493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.